{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"To assess participants with incidence of acute GvHD flare after CR/PR requiring additional agent (including 2.5 mg/kg/day of prednisone \\[or methylprednisolone equivalent of 2 mg/kg/day\\]) for systemic therapy before Day 56 post-administration of AP1903.\"","groups":[{"description":"Patients who did not move forward to DLI","id":"OG000","title":"Transplant Only"},{"description":"Proceeded to DLI per protocol","id":"OG001","title":"Transplat Plus DLI"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients who received AP1903","reportingStatus":"POSTED","timeFrame":"before Day 56 post AP1903","title":"To Assess the Incidence of Acute GvHD Flare After CR/PR Requiring Additional Agent for Systemic Therapy Before Day 56 Post-administration of AP1903.","type":"SECONDARY","unitOfMeasure":"Participants"}